Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Accumulated Expenses (2022 - 2026)

HeartSciences filings provide 5 years of Accumulated Expenses readings, the most recent being $200483.0 for Q1 2026.

  • On a quarterly basis, Accumulated Expenses fell 36.53% to $200483.0 in Q1 2026 year-over-year; TTM through Jan 2026 was $200483.0, a 36.53% decrease, with the full-year FY2025 number at $177628.0, down 55.41% from a year prior.
  • Accumulated Expenses hit $200483.0 in Q1 2026 for HeartSciences, up from $160261.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.1 million in Q2 2022 to a low of $5096.0 in Q4 2024.
  • Median Accumulated Expenses over the past 5 years was $451939.0 (2022), compared with a mean of $478528.4.
  • Biggest five-year swings in Accumulated Expenses: plummeted 99.34% in 2024 and later surged 3044.84% in 2025.
  • HeartSciences' Accumulated Expenses stood at $890654.0 in 2022, then fell by 13.25% to $772670.0 in 2023, then plummeted by 99.34% to $5096.0 in 2024, then surged by 3044.84% to $160261.0 in 2025, then increased by 25.1% to $200483.0 in 2026.
  • The last three reported values for Accumulated Expenses were $200483.0 (Q1 2026), $160261.0 (Q4 2025), and $599287.0 (Q3 2025) per Business Quant data.